KainosMed's Degenerative Brain Disease Treatment Also Effective for Cardiovascular Therapy
[Asia Economy Reporter Hyunseok Yoo] Kainosmed, which is pursuing a merger listing with Hana Financial No.11 SPAC, announced on the 13th that its degenerative brain disease treatment KM-819 showed inhibitory effects on chronic heart failure and acute heart failure (myocardial infarction) in animal experiments, confirming its potential as a cardiovascular treatment.
Heart failure is a serious heart disease caused by the heart's decreased pumping function, which fails to supply blood properly throughout the body. It is caused by heart overload in a hypertensive state or ischemic necrosis of heart cells due to myocardial infarction, leading to impaired heart function.
Kainosmed has conducted various experiments to develop KM-819, a FAF-1 inhibitor protein that promotes cell death, as a treatment for heart failure as part of its strategy to expand KM-819's indications, since it showed an effect of inhibiting ischemic necrosis in myocardial cells. As a result of measuring the heart failure inhibitory effect on rats with surgically induced chronic heart failure, KM-819 effectively suppressed the progression of heart failure compared to the untreated group and the control substance captopril (used to treat congestive heart failure). The inhibitory effect on myocardial cell hypertrophy caused by damage to myocardial cells due to heart failure was also confirmed.
In rats induced with acute heart failure, the myocardial infarction inhibitory effect of KM-819 was tested. In the experimental group administered KM-819 five minutes before myocardial infarction occurrence, coronary artery stenosis was significantly improved compared to the untreated group, which showed severe stenosis after myocardial infarction. The degree of improvement also showed a dose-efficacy dependence, improving as the dose of KM-819 increased.
Kainosmed is currently conducting efficacy evaluation in a myocardial infarction animal model at Yonsei University Cardiovascular Disease T2B-based Construction Center to decide on clinical entry, and plans to complete it in the first half of this year. A company official stated, "If excellent animal experiment results are secured in this experiment as well, we expect to receive IND approval for phase 2 clinical trials within this year and to enter phase 2 clinical trials from 2021." KM-819 has already been evaluated as a drug with very low toxicity in phase 1 clinical trials.
Kainosmed plans to conduct phase 2 clinical trials for Parkinson's disease treatment in the United States and simultaneously pursue phase 2 clinical trials in Korea for multiple system atrophy (MSA) treatment, expanding the indications of KM-819.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "If Both Spouses Work There, How Much Would They Make?" "They Earn More Than Me, and I'm a Doctor"... Envy Erupts Over Samsung Electronics' Bonus
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Meanwhile, Kainosmed plans to hold an extraordinary general meeting of shareholders on the 16th to process the merger agenda with Hana Financial No.11 SPAC.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
